| scholarly article | Q13442814 |
| P2093 | author name string | C Holmes | |
| C Dean | |||
| V H Perry | |||
| C Cunningham | |||
| D Culliford | |||
| E Zotova | |||
| S Kerr | |||
| J Woolford | |||
| P2860 | cites work | Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association | Q22241929 |
| Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease | Q27860795 | ||
| Differential regulation of AMPA receptor and GABA receptor trafficking by tumor necrosis factor-alpha | Q28241574 | ||
| Control of synaptic strength by glial TNFalpha | Q28570361 | ||
| Cognitive dysfunction and diabetes mellitus | Q30489305 | ||
| TNF-alpha stimulates caspase-3 activation and apoptotic cell death in primary septo-hippocampal cultures. | Q33181856 | ||
| Delirium in older medical inpatients and subsequent cognitive and functional status: a prospective study | Q33956430 | ||
| Aging and proinflammatory cytokines | Q34219483 | ||
| Clarifying confusion: the confusion assessment method. A new method for detection of delirium | Q34260568 | ||
| The epidemiology of the dementias: an update | Q34634824 | ||
| Systemic infection, interleukin 1beta, and cognitive decline in Alzheimer's disease. | Q35474257 | ||
| Actions of TNF-alpha on glutamatergic synaptic transmission in the central nervous system | Q36156231 | ||
| Systemic infections and inflammation affect chronic neurodegeneration | Q36707203 | ||
| Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson's disease | Q36741828 | ||
| Adiposity, hyperinsulinemia, diabetes and Alzheimer's disease: an epidemiological perspective | Q36776169 | ||
| Interleukin-6 covaries inversely with hippocampal grey matter volume in middle-aged adults | Q36925067 | ||
| Systemic inflammation induces acute behavioral and cognitive changes and accelerates neurodegenerative disease | Q37078772 | ||
| Alzheimer's disease and peripheral infections: the possible contribution from periodontal infections, model and hypothesis | Q37167113 | ||
| Predicting death from tumour necrosis factor-alpha and interleukin-6 in 80-year-old people | Q44373643 | ||
| Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins | Q44917427 | ||
| The metabolic syndrome, inflammation, and risk of cognitive decline | Q45145786 | ||
| Associations of plasma pro-inflammatory cytokines, fibrinogen, viscosity and C-reactive protein with cardiovascular risk factors and social deprivation: the fourth Glasgow MONICA study | Q46678880 | ||
| Inflammatory proteins in plasma and the risk of dementia: the rotterdam study | Q47591273 | ||
| Longitudinal study of inflammatory factors in serum, cerebrospinal fluid, and brain tissue in Alzheimer disease: interleukin-1beta, interleukin-6, interleukin-1 receptor antagonist, tumor necrosis factor-alpha, the soluble tumor necrosis factor rece | Q48376805 | ||
| Central and systemic endotoxin challenges exacerbate the local inflammatory response and increase neuronal death during chronic neurodegeneration. | Q48741510 | ||
| Exacerbation of motor neuron disease by chronic stimulation of innate immunity in a mouse model of amyotrophic lateral sclerosis. | Q51039637 | ||
| Plasma cytokines profile in older subjects with late onset Alzheimer's disease or vascular dementia. | Q51919320 | ||
| Serum TNF-alpha levels are increased and correlate negatively with free IGF-I in Alzheimer disease. | Q51945012 | ||
| A new rating scale for Alzheimer's disease. | Q53197509 | ||
| Neuritic plaque evolution in Alzheimer's disease is accompanied by transition of activated microglia from primed to enlarged to phagocytic forms. | Q53218426 | ||
| Increased plasma levels of interleukin-1, interleukin-6 and alpha-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain? | Q53233114 | ||
| Systemic immune aberrations in Alzheimer's disease patients. | Q53290628 | ||
| Re: Inflammatory markers and the risk of Alzheimer disease: the Framingham Study. | Q53293404 | ||
| Differences of peripheral inflammatory markers between mild cognitive impairment and Alzheimer's disease. | Q53392297 | ||
| Vascular risk factors and Alzheimer's disease | Q81217736 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Alzheimer's disease | Q11081 |
| systemic inflammation | Q7663815 | ||
| P304 | page(s) | 768-774 | |
| P577 | publication date | 2009-09-01 | |
| P1433 | published in | Neurology | Q1161692 |
| P1476 | title | Systemic inflammation and disease progression in Alzheimer disease | |
| P478 | volume | 73 |
| Q33813209 | 16S rRNA Next Generation Sequencing Analysis Shows Bacteria in Alzheimer's Post-Mortem Brain |
| Q46709105 | 18F-GE-180: a novel TSPO radiotracer compared to 11C-R-PK11195 in a preclinical model of stroke. |
| Q64235615 | A New Approach for the Diagnosis of Systemic and Oral Diseases Based on Salivary Biomolecules |
| Q55001725 | A New Venue of TNF Targeting. |
| Q64097766 | A Review and Hypothesized Model of the Mechanisms That Underpin the Relationship Between Inflammation and Cognition in the Elderly |
| Q34422142 | A critical role for human caspase-4 in endotoxin sensitivity |
| Q36979267 | A molecular mechanism for TNF-α-mediated downregulation of B cell responses |
| Q90324916 | A peripheral neutrophil-related inflammatory factor predicts a decline in executive function in mild Alzheimer's disease |
| Q42134649 | A single intraperitoneal injection of endotoxin in rats induces long-lasting modifications in behavior and brain protein levels of TNF-α and IL-18. |
| Q90932824 | A single systemic inflammatory insult causes acute motor deficits and accelerates disease progression in a mouse model of human tauopathy |
| Q50895004 | A static magnetic field attenuates lipopolysaccharide-induced neuro-inflammatory response via IL-6-mediated pathway. |
| Q34809312 | A systematic analysis of the peripheral and CNS effects of systemic LPS, IL-1β, [corrected] TNF-α and IL-6 challenges in C57BL/6 mice |
| Q37901097 | A transdisciplinary perspective of chronic stress in relation to psychopathology throughout life span development. |
| Q90282227 | Accelerated onset of CNS prion disease in mice co-infected with a gastrointestinal helminth pathogen during the preclinical phase |
| Q63432971 | Acute transient cognitive dysfunction and acute brain injury induced by systemic inflammation occur by dissociable IL-1-dependent mechanisms |
| Q36686081 | Adiponectin, leptin and IL-1 β in elderly diabetic patients with mild cognitive impairment. |
| Q47116886 | Adipose Tissue Inflammation Induces B Cell Inflammation and Decreases B Cell Function in Aging |
| Q60045502 | Advances in developing novel therapeutic strategies for Alzheimer's disease |
| Q27022410 | Age-dependent dysregulation of innate immunity |
| Q28071590 | Ageing, neurodegeneration and brain rejuvenation |
| Q35806803 | Aging impairs murine B cell differentiation and function in primary and secondary lymphoid tissues |
| Q40805941 | Akinetic crisis in dementia with Lewy bodies. |
| Q41929659 | Allergy influences the inflammatory status of the brain and enhances tau-phosphorylation. |
| Q52644596 | Alzheimer's Disease, Oligomers, and Inflammation. |
| Q35806684 | Alzheimer's Disease: Fatty Acids We Eat may be Linked to a Specific Protection via Low-dose Aspirin. |
| Q34753579 | Alzheimer's disease and infections, where we stand and where we go. |
| Q26827834 | Alzheimer's disease and periodontitis--an elusive link |
| Q41822193 | Alzheimer's disease biomarkers in animal models: closing the translational gap. |
| Q38975290 | Amelioration of LPS-induced inflammation response in microglia by AMPK activation |
| Q28384947 | Amyloid β: one of three danger-associated molecules that are secondary inducers of the proinflammatory cytokines that mediate Alzheimer's disease |
| Q37583628 | Analysis of the hippocampal proteome in ME7 prion disease reveals a predominant astrocytic signature and highlights the brain-restricted production of clusterin in chronic neurodegeneration |
| Q36431297 | Anesthesia, surgery, illness and Alzheimer's disease |
| Q39319443 | Apolipoprotein E4, Gender, Body Mass Index, Inflammation, Insulin Resistance, and Air Pollution Interactions: Recipe for Alzheimer's Disease Development in Mexico City Young Females |
| Q38960498 | Are Inflammation and Related Therapy Associated with All-Cause Dementia in a Primary Care Population? |
| Q91628220 | Are tumour necrosis factor inhibitor drugs associated with a lower risk of dementia? |
| Q37905123 | Assessing the contribution of inflammation in models of Alzheimer's disease |
| Q64093545 | Association Between Periodontitis and Cognitive Impairment in Adults: A Systematic Review |
| Q58736430 | Association between tooth loss and cognitive impairment in community-dwelling older Japanese adults: a 4-year prospective cohort study from the Ohasama study |
| Q35962639 | Associations between inflammatory markers, candidate polymorphisms and physical performance in older Danish twins |
| Q47951967 | Associations between pro-inflammatory cytokines, learning, and memory in late-life depression and healthy aging. |
| Q34293461 | At the extreme end of the psychoneuroimmunological spectrum: delirium as a maladaptive sickness behaviour response |
| Q38119019 | Atherosclerosis, biomarkers of atherosclerosis and Alzheimer's disease |
| Q47205582 | Autoimmune rheumatic diseases increase dementia risk in middle-aged patients: A nationwide cohort study. |
| Q35719609 | Baseline C-Reactive Protein Levels and Life Prognosis in Parkinson Disease. |
| Q37673274 | Basic mechanisms of neurodegeneration: a critical update |
| Q87754594 | Bayesian Cox Proportional Hazards Model in Survival Analysis of HACE1 Gene with Age at Onset of Alzheimer's Disease |
| Q38693438 | Biochemical and Radiological Markers of Alzheimer's Disease Progression |
| Q33771834 | Biomarkers of oxidative damage and inflammation in Alzheimer's disease |
| Q34277859 | Body fluid cytokine levels in mild cognitive impairment and Alzheimer's disease: a comparative overview |
| Q36608360 | Bone marrow transplantation confers modest benefits in mouse models of Huntington's disease |
| Q35106592 | Brain amyloidosis ascertainment from cognitive, imaging, and peripheral blood protein measures |
| Q41097407 | Brain and Peripheral Atypical Inflammatory Mediators Potentiate Neuroinflammation and Neurodegeneration |
| Q41217789 | Brain omega-3 polyunsaturated fatty acids modulate microglia cell number and morphology in response to intracerebroventricular amyloid-β 1-40 in mice. |
| Q35192822 | Brain region-specific alterations in the gene expression of cytokines, immune cell markers and cholinergic system components during peripheral endotoxin-induced inflammation |
| Q64933067 | Brain-Derived Neurotrophic Factor in Brain Disorders: Focus on Neuroinflammation. |
| Q35628333 | C-Reactive Protein Induces Tau Hyperphosphorylation via GSK3β Signaling Pathway in SH-SY5Y Cells |
| Q54957842 | C-Reactive Protein as a Therapeutic Target in Age-Related Macular Degeneration. |
| Q35734866 | C3-dependent mechanism of microglial priming relevant to multiple sclerosis. |
| Q35712471 | CCL2 is associated with a faster rate of cognitive decline during early stages of Alzheimer's disease |
| Q24309614 | CD74 interacts with APP and suppresses the production of Abeta |
| Q35200584 | CRP gene variation affects early development of Alzheimer's disease-related plaques. |
| Q91559320 | Calorie restriction slows age-related microbiota changes in an Alzheimer's disease model in female mice |
| Q40233829 | Can Better Management of Periodontal Disease Delay the Onset and Progression of Alzheimer's Disease? |
| Q33361553 | Can oral infection be a risk factor for Alzheimer's disease? |
| Q42752553 | Caspase-1 inhibition attenuates activation of BV2 microglia induced by LPS-treated RAW264.7 macrophages |
| Q43178937 | Central delivery of iodine-125-labeled cetuximab, etanercept and anakinra after perispinal injection in rats: possible implications for treating Alzheimer's disease |
| Q35059951 | Central pathways causing fatigue in neuro-inflammatory and autoimmune illnesses |
| Q36293312 | Cerebral magnetic resonance imaging in quiescent Crohn's disease patients with fatigue |
| Q50034510 | Cerebrospinal Fluid and Plasma Levels of Inflammation Differentially Relate to CNS Markers of Alzheimer's Disease Pathology and Neuronal Damage. |
| Q36120659 | Cerebrospinal fluid levels of IL-6 are decreased and correlate with cognitive status in DLB patients |
| Q89955963 | Characterization of the effects of calcitonin gene-related peptide receptor antagonist for Alzheimer's disease |
| Q34373769 | Cholesterol and copper affect learning and memory in the rabbit. |
| Q49349492 | Circulating levels of interleukin-17A, tumor necrosis factor-alpha, interleukin-18, interleukin-10, and cognitive performance of patients with relapsing-remitting multiple sclerosis. |
| Q38388693 | Co-morbidity and systemic inflammation as drivers of cognitive decline: new experimental models adopting a broader paradigm in dementia research. |
| Q39898175 | Cognitive Impairment in Patients with Psoriasis: A Cross-Sectional Study Using the Montreal Cognitive Assessment. |
| Q38805023 | Cognitive decline in heart failure |
| Q36443732 | Cognitive dysfunction with aging and the role of inflammation |
| Q92570415 | Comorbidities in inflammatory bowel disease: a call for action |
| Q54113689 | Could Alzheimer's Disease Originate in the Periphery and If So How So? |
| Q51738645 | Counteracting the effects of TNF receptor-1 has therapeutic potential in Alzheimer's disease. |
| Q40540158 | Coxsackievirus Adenovirus Receptor Loss Impairs Adult Neurogenesis, Synapse Content, and Hippocampus Plasticity. |
| Q54942608 | Current Concepts of Neurodegenerative Mechanisms in Alzheimer's Disease. |
| Q51110008 | DNA methylation of the TNF-α promoter region in peripheral blood monocytes and the cortex of human Alzheimer's disease patients. |
| Q36311288 | DNA sensors are expressed in astrocytes and microglia in vitro and are upregulated during gliosis in neurodegenerative disease |
| Q38062817 | Deciphering the mechanism underlying late-onset Alzheimer disease |
| Q57812922 | Decreased Levels of Circulating Adiponectin in Mild Cognitive Impairment and Alzheimer’s Disease |
| Q46124252 | Decreased neurite density within frontostriatal networks is associated with executive dysfunction in temporal lobe epilepsy. |
| Q60919923 | Delirium is associated with frequency band specific dysconnectivity in intrinsic connectivity networks: preliminary evidence from a large retrospective pilot case-control study |
| Q46735176 | Dementia: A link between microbial infection and cognition? |
| Q48066803 | Depression as a risk factor for Alzheimer's disease: Genes, steroids, cytokines and neurogenesis - What do we need to know? |
| Q34394080 | Developing novel blood-based biomarkers for Alzheimer's disease |
| Q89388307 | Diaphanous 1 (DIAPH1) is Highly Expressed in the Aged Human Medial Temporal Cortex and Upregulated in Myeloid Cells During Alzheimer's Disease |
| Q36457368 | Dietary omega 3 polyunsaturated fatty acids and Alzheimer's disease: interaction with apolipoprotein E genotype |
| Q39645788 | Distinct modulation of microglial amyloid β phagocytosis and migration by neuropeptides (i). |
| Q59128213 | Diverse Protein Profiles in CNS Myeloid Cells and CNS Tissue From Lipopolysaccharide- and Vehicle-Injected APP/PS1 Transgenic Mice Implicate Cathepsin Z in Alzheimer's Disease |
| Q36835430 | Dnr1 mutations cause neurodegeneration in Drosophila by activating the innate immune response in the brain. |
| Q43677900 | Does Helicobacter pylori infection increase incidence of dementia? The Personnes Agées QUID Study. |
| Q38057607 | Drug repositioning for Alzheimer's disease. |
| Q33797110 | Early diagnosis of mild cognitive impairment and Alzheimer's disease based on salivary lactoferrin |
| Q58691858 | Effects of Tea Catechins on Alzheimer's Disease: Recent Updates and Perspectives |
| Q34059086 | Effects of collagen-induced rheumatoid arthritis on amyloidosis and microvascular pathology in APP/PS1 mice. |
| Q37694042 | Enhanced susceptibility of triple transgenic Alzheimer's disease (3xTg-AD) mice to acute infection. |
| Q37219038 | Environmental Enrichment Potently Prevents Microglia-Mediated Neuroinflammation by Human Amyloid β-Protein Oligomers |
| Q35671005 | Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trial |
| Q89693489 | Evaluating Mechanisms of Postoperative Delirium and Cognitive Dysfunction Following Elective Spine Surgery in Elderly Patients (CONFESS): Protocol for a Prospective Observational Trial |
| Q35057271 | Exacerbation of CNS inflammation and neurodegeneration by systemic LPS treatment is independent of circulating IL-1β and IL-6. |
| Q47657930 | Examining the Relationship between Trace Lithium in Drinking Water and the Rising Rates of Age-Adjusted Alzheimer's Disease Mortality in Texas |
| Q64072899 | Exploiting microglial and peripheral immune cell crosstalk to treat Alzheimer's disease |
| Q28079218 | Exploring Biomarkers for Alzheimer's Disease |
| Q36164195 | Extensive innate immune gene activation accompanies brain aging, increasing vulnerability to cognitive decline and neurodegeneration: a microarray study |
| Q38723000 | FTY720 Attenuates Infection-Induced Enhancement of Aβ Accumulation in APP/PS1 Mice by Modulating Astrocytic Activation. |
| Q30395912 | Fetal thymus graft enables recovery from age-related hearing loss and expansion of CD4-Positive T cells expressing IL-1 receptor type 2 and regulatory T Cells |
| Q64084540 | Forebrain Cholinergic Signaling Regulates Innate Immune Responses and Inflammation |
| Q26748713 | Fundamental role of pan-inflammation and oxidative-nitrosative pathways in neuropathogenesis of Alzheimer's disease |
| Q26747585 | Fundamental role of pan-inflammation and oxidative-nitrosative pathways in neuropathogenesis of Alzheimer's disease in focal cerebral ischemic rats |
| Q37334523 | G protein-coupled receptor kinase 2 and group I metabotropic glutamate receptors mediate inflammation-induced sensitization to excitotoxic neurodegeneration |
| Q35136695 | Galantamine alleviates inflammation and other obesity-associated complications in high-fat diet-fed mice. |
| Q99239419 | Gene expression of serotonergic markers in peripheral blood mononuclear cells of patients with late-onset Alzheimer's disease |
| Q33804040 | Gene-physical activity interactions in lower extremity performance: inflammatory genes CRP, TNF-α, and LTA in community-dwelling elders. |
| Q26767289 | Genetic and Transcriptomic Profiles of Inflammation in Neurodegenerative Diseases: Alzheimer, Parkinson, Creutzfeldt-Jakob and Tauopathies |
| Q37591588 | Genetic effect of interleukin-1 beta (C-511T) polymorphism on the structural covariance network and white matter integrity in Alzheimer's disease |
| Q24629875 | Genetics of late-onset Alzheimer's disease: update from the alzgene database and analysis of shared pathways |
| Q52145262 | Gx-50 reduces β-amyloid-induced TNF-α, IL-1β, NO, and PGE2 expression and inhibits NF-κB signaling in a mouse model of Alzheimer's disease. |
| Q55315794 | How does cytomegalovirus factor into diseases of aging and vaccine responses, and by what mechanisms? |
| Q36630566 | How predictive of dementia are peripheral inflammatory markers in the elderly? |
| Q47124444 | Human Induced Pluripotent Stem Cells and the Modelling of Alzheimer's Disease: The Human Brain Outside the Dish |
| Q36198753 | Human gut microbiota: the links with dementia development |
| Q64287877 | Hyperactive Innate Immunity Causes Degeneration of Dopamine Neurons upon Altering Activity of Cdk5 |
| Q90250087 | Identification of stable reference genes for lipopolysaccharide-stimulated macrophage gene expression studies |
| Q38492631 | Immune attack: the role of inflammation in Alzheimer disease. |
| Q59810560 | Immunosenescence of Natural Killer Cells, Inflammation, and Alzheimer's Disease |
| Q26825419 | Impact of age-related neuroglial cell responses on hippocampal deterioration |
| Q91129691 | Implications of sleep disturbance and inflammation for Alzheimer's disease dementia |
| Q33578336 | Increased inflammatory response in cytomegalovirus seropositive patients with Alzheimer's disease |
| Q41189702 | Increased risk of dementia among patients with pulmonary tuberculosis: a retrospective population-based cohort study. |
| Q90479650 | Increasing Tau 4R Tau Levels Exacerbates Hippocampal Tau Hyperphosphorylation in the hTau Model of Tauopathy but Also Tau Dephosphorylation Following Acute Systemic Inflammation |
| Q41193099 | Individual Cytokines Modulate the Neurological Symptoms of ATM Deficiency in a Region Specific Manner(1,2,3) |
| Q58580212 | Infection Augments Expression of Mechanosensing Piezo1 Channels in Amyloid Plaque-Reactive Astrocytes |
| Q64936811 | Infection-Induced Systemic Inflammation Is a Potential Driver of Alzheimer's Disease Progression. |
| Q38373189 | Infections Up to 76 Days After Stroke Increase Disability and Death. |
| Q36225887 | Inflammaging decreases adaptive and innate immune responses in mice and humans |
| Q37982378 | Inflammation and adaptive immunity in Parkinson's disease |
| Q37069901 | Inflammation and clinical presentation in neurodegenerative disease: a volatile relationship |
| Q36380719 | Inflammation and cognitive functioning in African Americans and Caucasians |
| Q50425779 | Inflammation is associated with a worsening of presbycusis: evidence from the MRC national study of hearing. |
| Q30524688 | Inflammation-induced dysfunction of the low-density lipoprotein receptor-related protein-1 at the blood-brain barrier: protection by the antioxidant N-acetylcysteine |
| Q40507310 | Inflammatory Markers in Mild Cognitive Impairment: A Meta-Analysis |
| Q50563391 | Influence of Allergy on Immunoglobulins and Amyloid-β in the Cerebrospinal Fluid of Patients with Alzheimer's Disease. |
| Q64078334 | Inhibition of DYRK1A proteolysis modifies its kinase specificity and rescues Alzheimer phenotype in APP/PS1 mice |
| Q38223011 | Innate immune activation in neurodegenerative disease |
| Q37977265 | Innate immunity and the etiology of late-onset Alzheimer's disease. |
| Q38358574 | Innate immunity in Alzheimer's disease |
| Q39314130 | Innate immunity in Alzheimer's disease: the relevance of animal models? |
| Q38040993 | Innate inflammation in Parkinson's disease |
| Q38401306 | Interrelation of oxidative stress and inflammation in neurodegenerative disease: role of TNF. |
| Q37491413 | Investigation of the effects of a high fish diet on inflammatory cytokines, blood pressure, and lipids in healthy older Australians |
| Q90679397 | Is Alzheimer disease a failure of mobilizing immune defense? Lessons from cognitively fit oldest-old |
| Q34019193 | Is Alzheimer's disease a systemic disease? |
| Q92800212 | Is Innate Memory a Double-Edge Sword in Alzheimer's Disease? A Reappraisal of New Concepts and Old Data |
| Q38592446 | Is membrane homeostasis the missing link between inflammation and neurodegenerative diseases? |
| Q56925055 | It's Never Too Early or Too Late-End the Epidemic of Alzheimer's by Preventing or Reversing Causation From Pre-birth to Death |
| Q92234249 | Key inflammatory pathway activations in the MCI stage of Alzheimer's disease |
| Q37398321 | Leptomeningeal cells transduce peripheral macrophages inflammatory signal to microglia in reponse to Porphyromonas gingivalis LPS. |
| Q64265598 | Lipopolysaccharide-induced neuroinflammation induces presynaptic disruption through a direct action on brain tissue involving microglia-derived interleukin 1 beta |
| Q36456166 | Long-term PM2.5 Exposure and Neurological Hospital Admissions in the Northeastern United States |
| Q48777899 | Long-term cerebral consequences of sepsis. |
| Q24628579 | Long-term cognitive impairment and functional disability among survivors of severe sepsis |
| Q36226660 | Long-term impact of systemic bacterial infection on the cerebral vasculature and microglia. |
| Q34475359 | Longitudinal inflammation, cognitive decline, and Alzheimer's disease: a mini-review |
| Q38923620 | Longitudinal relationship of severe periodontitis with cognitive decline in older Japanese |
| Q55250117 | Low-grade systemic inflammation is associated with functional disability in elderly people affected by dementia. |
| Q47926820 | Macrophage Migration Inhibitory Factor is Associated with Biomarkers of Alzheimer's Disease Pathology and Predicts Cognitive Decline in Mild Cognitive Impairment and Mild Dementia. |
| Q28730725 | Maintaining brain health by monitoring inflammatory processes: a mechanism to promote successful aging |
| Q35579238 | Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial |
| Q48242608 | Mast cells participate in chronic low-grade inflammation within adipose tissue. |
| Q46796358 | Mechanisms of association between physical functioning and breast cancer mortality: evidence from the Women's Healthy Eating and Living Study |
| Q37849615 | Mechanisms of neurodegeneration shared between multiple sclerosis and Alzheimer's disease |
| Q91742867 | Metabolic requirements of human pro-inflammatory B cells in aging and obesity |
| Q33625557 | Metaflammasome components in the human brain: a role in dementia with Alzheimer's pathology? |
| Q38287691 | MicroRNAs: Roles in Regulating Neuroinflammation. |
| Q92540215 | Microbiota-gut-brain axis and toll-like receptors in Alzheimer's disease |
| Q92649247 | Microglia Express Insulin-Like Growth Factor-1 in the Hippocampus of Aged APPswe/PS1ΔE9 Transgenic Mice |
| Q37093985 | Microglia and macrophages of the central nervous system: the contribution of microglia priming and systemic inflammation to chronic neurodegeneration. |
| Q38016812 | Microglia and neurodegeneration: the role of systemic inflammation. |
| Q36072124 | Microglia in Alzheimer's Disease: It's All About Context |
| Q37710380 | Microglia in neurodegenerative disease |
| Q36400800 | Microglia in the degenerating brain are capable of phagocytosis of beads and of apoptotic cells, but do not efficiently remove PrPSc, even upon LPS stimulation. |
| Q26739495 | Microglial Priming and Alzheimer's Disease: A Possible Role for (Early) Immune Challenges and Epigenetics? |
| Q38203788 | Microglial dynamics and role in the healthy and diseased brain: a paradigm of functional plasticity |
| Q38196699 | Microglial priming in neurodegenerative disease |
| Q36286370 | Mitoxantrone repression of astrocyte activation: relevance to multiple sclerosis |
| Q38793420 | Molecular Anti-inflammatory Mechanisms of Retinoids and Carotenoids in Alzheimer's Disease: a Review of Current Evidence |
| Q36771721 | Molecular Signaling Mechanisms of Natural and Synthetic Retinoids for Inhibition of Pathogenesis in Alzheimer's Disease |
| Q35840623 | Molecular imaging in Alzheimer's disease: new perspectives on biomarkers for early diagnosis and drug development. |
| Q37224020 | Monocyte Phenotype and Polyfunctionality Are Associated With Elevated Soluble Inflammatory Markers, Cytomegalovirus Infection, and Functional and Cognitive Decline in Elderly Adults |
| Q28397785 | NRF2-regulation in brain health and disease: implication of cerebral inflammation |
| Q36028985 | Neurocognitive impairment in HIV-infected individuals with previous syphilis |
| Q42854665 | Neuroinflammation and Aβ accumulation linked to systemic inflammation are decreased by genetic PKR down-regulation |
| Q28259238 | Neuroinflammation in Alzheimer's disease |
| Q38202910 | Neuroinflammation in Alzheimer's disease: from pathogenesis to a therapeutic target |
| Q33965321 | Neuroinflammation resulting from covert brain invasion by common viruses - a potential role in local and global neurodegeneration |
| Q48140242 | Neuroinflammatory and behavioural changes in the Atp7B mutant mouse model of Wilson's disease. |
| Q36069541 | Neurological impacts from inhalation of pollutants and the nose-brain connection |
| Q39908937 | Neuroprotective Effects of Endurance Exercise Against High-Fat Diet-Induced Hippocampal Neuroinflammation |
| Q92702025 | Neuroprotective Role of the Nrf2 Pathway in Subarachnoid Haemorrhage and Its Therapeutic Potential |
| Q48932169 | Neuroprotective effect of peptides extracted from walnut (Juglans Sigilata Dode) proteins on Aβ25-35-induced memory impairment in mice. |
| Q34757939 | Neuroprotective strategies involving ROS in Alzheimer disease |
| Q40194358 | Neurosyphilis Increases Human Immunodeficiency Virus (HIV)-associated Central Nervous System Inflammation but Does Not Explain Cognitive Impairment in HIV-infected Individuals With Syphilis |
| Q58704615 | Neutrophil-to-lymphocyte ratio predicts diagnosis and prognosis of idiopathic sudden sensorineural hearing loss: A systematic review and meta-analysis |
| Q26822022 | Non-steroidal anti-inflammatory drugs and cognitive function: are prostaglandins at the heart of cognitive impairment in dementia and delirium? |
| Q49652662 | Nutrition: Review on the Possible Treatment for Alzheimer's Disease. |
| Q35204568 | One is the deadliest number: the detrimental effects of social isolation on cerebrovascular diseases and cognition |
| Q44103033 | Oral health condition of French elderly and risk of dementia: a longitudinal cohort study |
| Q99404568 | Osteoarthritis Was Associated With a Faster Decline in Hippocampal Volumes in Cognitively Normal Older People |
| Q35231254 | Osteoarthritis accelerates and exacerbates Alzheimer's disease pathology in mice. |
| Q35617320 | Osteoarthritis increases the risk of dementia: a nationwide cohort study in Taiwan |
| Q41141816 | Oxidative Stress in Neurodegenerative Diseases: From Molecular Mechanisms to Clinical Applications |
| Q47753241 | PDK1 decreases TACE-mediated α-secretase activity and promotes disease progression in prion and Alzheimer's diseases |
| Q46093504 | Pathogenesis and Therapeutic Strategies in Alzheimer's Disease: From Brain to Periphery |
| Q48636358 | Periodontal Disease Associated with Higher Risk of Dementia: Population-Based Cohort Study in Taiwan. |
| Q97419721 | Periodontal Disease and Periodontal Disease-Related Bacteria Involved in the Pathogenesis of Alzheimer's Disease |
| Q26744852 | Periodontal disease's contribution to Alzheimer's disease progression in Down syndrome |
| Q40966991 | Periodontitis Is Associated with Cognitive Impairment in Elderly Koreans: Results from the Yangpyeong Cohort Study |
| Q42776392 | Periodontitis and Alzheimer's Disease: A Possible Comorbidity between Oral Chronic Inflammatory Condition and Neuroinflammation. |
| Q35952361 | Periodontitis and Cognitive Decline in Alzheimer's Disease. |
| Q26829871 | Perioperative cognitive trajectory in adults |
| Q48292563 | Peripheral administration of the soluble TNF inhibitor XPro1595 modifies brain immune cell profiles, decreases beta-amyloid plaque load, and rescues impaired long-term potentiation in 5xFAD mice |
| Q38094970 | Peripheral inflammation in neurodegeneration. |
| Q47284845 | Peripheral inflammation in prodromal Alzheimer's and Lewy body dementias |
| Q92182516 | Peripheral inflammatory biomarkers in Alzheimer's disease: a brief review |
| Q42173710 | Peripheral inflammatory markers indicate microstructural damage within periventricular white matter hyperintensities in Alzheimer's disease: A preliminary report |
| Q37762260 | Perispinal etanercept: a new therapeutic paradigm in neurology |
| Q90644110 | Perspective: Is therapeutic plasma exchange a viable option for treating Alzheimer's disease? |
| Q37204006 | Perspectives on the Tertiary Prevention Strategy for Alzheimer's Disease. |
| Q36615483 | Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer's-like pathology |
| Q39082255 | Phenolic-enriched fractions from brewers' spent grain possess cellular antioxidant and immunomodulatory effects in cell culture model systems |
| Q28385504 | Physiologic dysfunction scores and cognitive function test performance in U.S. adults |
| Q36073671 | Physiological amyloid-beta clearance in the periphery and its therapeutic potential for Alzheimer's disease |
| Q90289879 | Plasma Markers of Inflammation Linked to Clinical Progression and Decline During Preclinical AD |
| Q37158584 | Plasma acetylcholinesterase activity correlates with intracerebral β-amyloid load |
| Q64064010 | Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer's disease |
| Q36420162 | Plasma neopterin level as a marker of peripheral immune activation in amnestic mild cognitive impairment and Alzheimer's disease. |
| Q36888445 | Plasma signaling proteins in persons at genetic risk for Alzheimer disease: influence of APOE genotype |
| Q28083786 | Porphyromonas gingivalis Periodontal Infection and Its Putative Links with Alzheimer's Disease |
| Q38051213 | Post-marketing assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: an updated review |
| Q35519004 | Post-mortem analysis of neuroinflammatory changes in human Alzheimer's disease |
| Q61357069 | Postoperative delirium |
| Q33687436 | Potential future neuroprotective therapies for neurodegenerative disorders and stroke |
| Q91762131 | Potential therapeutic roles of retinoids for prevention of neuroinflammation and neurodegeneration in Alzheimer's disease |
| Q33785755 | Presenilin 2 is the predominant γ-secretase in microglia and modulates cytokine release |
| Q33918695 | Presenilin/gamma-Secretase and Inflammation |
| Q48479593 | Preventive effects of dexmedetomidine on the development of cognitive dysfunction following systemic inflammation in aged rats. |
| Q38862634 | Preventive strategies and potential therapeutic interventions for delirium in sepsis |
| Q61709413 | Pro-inflammatory activation of microglia in the brain of patients with sepsis. |
| Q37095837 | Progranulin mutations as risk factors for Alzheimer disease |
| Q35104455 | Proinflammatory cytokines, sickness behavior, and Alzheimer disease |
| Q47213450 | Protective effect of antirheumatic drugs on dementia in rheumatoid arthritis patients |
| Q98176768 | Psychiatric face of COVID-19 |
| Q38119472 | Quantitative metabolic profiling of lipid mediators. |
| Q38034108 | Quintessential risk factors: their role in promoting cognitive dysfunction and Alzheimer's disease |
| Q92510163 | Re-thinking the Etiological Framework of Neurodegeneration |
| Q48000590 | Recent Advances in the Inhibition of p38 MAPK as a Potential Strategy for the Treatment of Alzheimer's Disease |
| Q38245624 | Recent advances in the neuroimmunology of cell-surface CNS autoantibody syndromes, Alzheimer's disease, traumatic brain injury and schizophrenia |
| Q50684551 | Relation of Poor Memory to Soluble Tumor Necrosis Factor Receptor Type Two (sTNF-RII). |
| Q64076963 | Relationships Between Ion Channels, Mitochondrial Functions and Inflammation in Human Aging |
| Q92061664 | Resolution of Inflammation in Neurodegenerative Diseases: The Role of Resolvins |
| Q41343333 | Resveratrol effects on astrocyte function: relevance to neurodegenerative diseases |
| Q38068503 | Review: activation patterns of microglia and their identification in the human brain. |
| Q38050498 | Review: systemic inflammation and Alzheimer's disease |
| Q28067321 | Role of berberine in Alzheimer's disease |
| Q37680099 | Role of neuroinflammation in neurodegeneration: new insights |
| Q28393808 | Role of platelets in neuroinflammation: a wide-angle perspective |
| Q26799870 | Role of pro-inflammatory cytokines released from microglia in Alzheimer's disease |
| Q41762801 | Rosiglitazone rescues memory impairment in Alzheimer's transgenic mice: mechanisms involving a reduced amyloid and tau pathology |
| Q60046944 | Rusty Microglia: Trainers of Innate Immunity in Alzheimer's Disease |
| Q88983835 | Salivary biomarkers for the diagnosis and monitoring of neurological diseases |
| Q53347422 | Selective acetyl- and butyrylcholinesterase inhibitors reduce amyloid-β ex vivo activation of peripheral chemo-cytokines from Alzheimer's disease subjects: exploring the cholinergic anti-inflammatory pathway. |
| Q39421902 | Senescent B cells in aging and age-related diseases: Their role in the regulation of antibody responses |
| Q37015867 | Serum antibodies to periodontal pathogens are a risk factor for Alzheimer's disease |
| Q39901740 | Serum immune markers and disease progression in an incident Parkinson's disease cohort (ICICLE-PD). |
| Q90331098 | Sex-specific hippocampal metabolic signatures at the onset of systemic inflammation with lipopolysaccharide in the APPswe/PS1dE9 mouse model of Alzheimer's disease |
| Q57143986 | Sexual dimorphism in predisposition to Alzheimer's disease |
| Q26784170 | Shared Neuropathological Characteristics of Obesity, Type 2 Diabetes and Alzheimer's Disease: Impacts on Cognitive Decline |
| Q47335457 | Similarity and Differences in Inflammation-Related Characteristics of the Peripheral Immune System of Patients with Parkinson's and Alzheimer's Diseases |
| Q37249172 | Sirtuin deacetylases as therapeutic targets in the nervous system |
| Q59795046 | Soluble Fibrinogen Triggers Non-cell Autonomous ER Stress-Mediated Microglial-Induced Neurotoxicity |
| Q93167790 | Study protocol: ASCRIBED: the impact of Acute SystematiC inflammation upon cerebRospinal fluId and blood BiomarkErs of brain inflammation and injury in dementia: a study in acute hip fracture patients |
| Q57816573 | Systemic Inflammation Is Associated With Longitudinal Changes in Cognitive Performance Among Urban Adults |
| Q47642585 | Systemic Inflammation and Multimodal Biomarkers in Amnestic Mild Cognitive Impairment and Alzheimer's Disease. |
| Q37524082 | Systemic TNF-α produces acute cognitive dysfunction and exaggerated sickness behavior when superimposed upon progressive neurodegeneration |
| Q37954456 | Systemic and central immunity in Alzheimer's disease: therapeutic implications |
| Q35906528 | Systemic challenge with the TLR3 agonist poly I:C induces amplified IFNalpha/beta and IL-1beta responses in the diseased brain and exacerbates chronic neurodegeneration |
| Q58760287 | Systemic infection modifies the neuroinflammatory response in late stage Alzheimer's disease |
| Q53320962 | Systemic inflammation and Alzheimer's disease. |
| Q92060690 | Systemic inflammation and causal risk for Alzheimer's dementia: Possibilities and limitations of a Mendelian randomization approach |
| Q37905132 | Systemic inflammation and delirium: important co-factors in the progression of dementia. |
| Q34463760 | Systemic inflammation and the brain: novel roles of genetic, molecular, and environmental cues as drivers of neurodegeneration |
| Q40482561 | Systemic inflammation impairs attention and cognitive flexibility but not associative learning in aged rats: possible implications for delirium. |
| Q51736517 | Systemic inflammation induced by lipopolysaccharide aggravates inherited retinal dystrophy. |
| Q48761733 | Systemic inflammation induces axon injury during brain inflammation. |
| Q90559093 | T cells in Alzheimer's disease: space invaders |
| Q26823723 | TDP-43: a new player on the AD field? |
| Q41694180 | TNFα affects CREB-mediated neuroprotective signaling pathways of synaptic plasticity in neurons as revealed by proteomics and phospho-proteomics |
| Q48029728 | TREM2 expression in the human brain: a marker of monocyte recruitment? |
| Q47188911 | Targeting Neuroinflammation to Treat Alzheimer's Disease. |
| Q26744219 | Targeting innate immunity for neurodegenerative disorders of the central nervous system |
| Q28078474 | Targeting neuroinflammation in Alzheimer's disease |
| Q38366835 | The Antiinflammatory Properties of Humic Substances: A Mini Review |
| Q45931909 | The Cholinergic System Modulates Memory and Hippocampal Plasticity via Its Interactions with Non-Neuronal Cells. |
| Q39324087 | The IL-1β phenomena in neuroinflammatory diseases |
| Q50669014 | The Independent Role of Inflammation in Physical Frailty among Older Adults with Mild Cognitive Impairment and Mild-to-Moderate Alzheimer's Disease. |
| Q55130777 | The Inflammatory Nature of Post-surgical Delirium Predicts Benefit of Agents With Anti-TNF Effects, Such as Dexmedetomidine. |
| Q38671719 | The Lipoxygenases: Their Regulation and Implication in Alzheimer's Disease. |
| Q64105293 | The Modulatory Effect of Gender and Cytomegalovirus-Seropositivity on Circulating Inflammatory Factors and Cognitive Performance in Elderly Individuals |
| Q90599917 | The Receptor for Advanced Glycation Endproducts (RAGE) and Mediation of Inflammatory Neurodegeneration |
| Q55294882 | The Role of Immunosenescence in Neurodegenerative Diseases. |
| Q33737263 | The Role of Interleukin-18, Oxidative Stress and Metabolic Syndrome in Alzheimer's Disease |
| Q39424451 | The Role of Microglia in Prion Diseases: A Paradigm of Functional Diversity |
| Q46141259 | The Role of Nitric Oxide from Neurological Disease to Cancer |
| Q26753199 | The blood-brain barrier in systemic inflammation |
| Q34993643 | The effect of non-steroidal anti-inflammatory agents on behavioural changes and cytokine production following systemic inflammation: Implications for a role of COX-1 |
| Q40465097 | The effect of systemic inflammation on human brain barrier function |
| Q90098412 | The endotoxin hypothesis of neurodegeneration |
| Q35064995 | The evolving biology of microglia in Alzheimer's disease. |
| Q37830018 | The human microbiome in multiple sclerosis: pathogenic or protective constituents? |
| Q35860997 | The immunology of neurodegeneration |
| Q34562975 | The impact of age-related dysregulation of the angiotensin system on mitochondrial redox balance |
| Q38123243 | The impact of neuroimmune changes on development of amyloid pathology; relevance to Alzheimer's disease. |
| Q38609436 | The importance of postoperative quality of recovery: influences, assessment, and clinical and prognostic implications |
| Q50102950 | The influence of TNF inhibitors on dementia incidence in patients with rheumatoid arthritis; an analysis from the BSRBR-RA. |
| Q38156518 | The influence of cannabinoids on generic traits of neurodegeneration |
| Q92493391 | The intestinal microbiome and Alzheimer's disease: A review |
| Q92518346 | The neuro-glial coagulonome: the thrombin receptor and coagulation pathways as major players in neurological diseases |
| Q37091521 | The relationship between Helicobacter pylori infection and Alzheimer's disease in Japan. |
| Q38105903 | The role of inflammation in sporadic and familial Parkinson's disease |
| Q37765627 | The role of inflammation in the pathogenesis of delirium and dementia in older adults: a review. |
| Q42932695 | The role of tumor necrosis factor-alpha in cognitive improvement after peroxisome proliferator-activator receptor gamma agonist pioglitazone treatment in Alzheimer's disease |
| Q64990947 | The troubling story of blood-driven dementias. |
| Q64067670 | Therapeutic Inhibition of the Complement System in Diseases of the Central Nervous System |
| Q37678539 | Therapeutic implications of the prostaglandin pathway in Alzheimer's disease |
| Q35698522 | Therapeutic potential of mGluR5 targeting in Alzheimer's disease |
| Q40302712 | Tooth Loss and Risk of Dementia in the Community: the Hisayama Study |
| Q30543926 | Transcriptomics of cortical gray matter thickness decline during normal aging |
| Q37839130 | Treating inflammation in childhood neurodegenerative disorders |
| Q38607117 | Treating the whole body in Huntington's disease |
| Q39547833 | Treatment for Rheumatoid Arthritis and Risk of Alzheimer's Disease: A Nested Case-Control Analysis |
| Q92603575 | Tumor Necrosis Factor-Alpha Alters Electrophysiological Properties of Rabbit Hippocampal Neurons |
| Q35031990 | Tumour necrosis factor-α (TNF-α) and miRNA expression in frontal and temporal neocortex in Alzheimer's disease and the effect of TNF-α on miRNA expression in vitro |
| Q91646701 | Understanding the Physiological Links Between Physical Frailty and Cognitive Decline |
| Q37985635 | Viral and inflammatory triggers of neurodegenerative diseases |
| Q39328741 | Volunteering Is Associated with Lower Risk of Cognitive Impairment |
| Q42026475 | Whether, when and how chronic inflammation increases the risk of developing late-onset Alzheimer's disease |
| Q38759253 | YKL-40 as a Potential Biomarker and a Possible Target in Therapeutic Strategies of Alzheimer's Disease |
Search more.